Company intelligence / Profile preview
Beijing New Weipao Pharmaceutical Technology
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing New Weipao Pharmaceutical Technology is a Chinese biotechnology company focused on the development of innovative small molecule therapeutics for metabolic diseases. The company specializes in the discovery of multi-target agonists, particularly those targeting the GLP-1, GIP, and glucagon receptors, to treat conditions such as type 2 diabetes and obesity. By leveraging its expertise in medicinal chemistry, New Weipao aims to create oral alternatives to existing injectable peptide therapies. The company is currently advancing several candidates through the pre-clinical stage to address the growing global burden of metabolic disorders.
- Therapeutic areas
- EndocrinologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Beijing New Weipao Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing New Weipao Pharmaceutical Technology.